ãã»ã«ãã±ã¢ããã§ã³ã¬ãŒãã§ããããæªåããçç±.é£äºã®ããããžã®åœ±é¿ãšè¡ç³å€ã®é¢ä¿æ§
Â
Â
Â
ã·ããŒãŒ( ^Ï^ )
Â
æ±ããè¬å€åž«saitorioãšç³ããŸãã
Â
Â
Â
Â
Â
ä»åã¯ãããã±ã¢ã·ãªãŒãºã®é£äºç·š
ããã§ã³ã¬ãŒãã§ãããæªåããã®ãïŒã
Â
ã§ã( ïœãŒÂŽ)ã
Â
Â
ãã®æèšã£ãŠè¯ãè³ã«ããŸãããïŒ
Â
ç¹ã«èŠªãã(ç¬)
Â
Â
ãã®èšäºã§åŸãããããšã¯
â ãã§ã³ã¬ãŒããšãããé¢ä¿æ§
â è¡ç³å€ã¯ãããã«åœ±é¿ããã®ã
â é£äºããèŠçŽãããã«ã¯
Â
Â
çããã®é£ã¹ãããããããã§ããã¯
æãããŠãããªã®ãïŒ
Â
Â
ãã§ã³ãšãã©ã»ãïŒåœç©ïŒã®
ã¯ãã¹ãªãŒããŒè©Šéšãããš
Â
é«ã€ã³ã¹ãªã³è¡ç仮説ã®
芳ç¹ãã解説ããŸããã
Â
Â
Â
éå»ã®é¢é£èšäºã¯ãã¡ãã§ã
Â
Â
Â
Â
ãã£ã³ãã«ç»é²( ïœã»âã»ÂŽ)ïŸïŸïŸïœŒïœž
Â
ä»åç»å Žããé«ã€ã³ã¹ãªã³è¡ç
äœGIã«ã€ããŠè§£èª¬ããåç»ã§ãã
Â
Â
Â
Â
å¿æŽãããããé¡ãããŸãïŒïŒïŒ
Â
Â
[è¬ã飲ã¿å¿ããªãããã«ãã]
— æ±ããðŠè¬å€åž«saitorioïŒ å¥åº·ãªãã©ã·ãŒÃããã°ÃYouTube (@saitorio3) 2020幎4æ18æ¥
âïžæ¯æ¥å¿ ãããç¿æ £ã«çµã¿èŸŒã
è¯ãå€åºã®ãšãããã£ããè¬ã
æã¡å¿ããŠããŸãã£ãŠèšããã
ãããªãšãã¯æ¯æãïŒæ¥åã
容åšã«å ¥ããŠæã¡æ©ããšãã
æ¯æã®ããšãšãªãã°ããã¯ã
æ¯ç£šããããã®ãšåãã
å ¥ãå¿ãã
ã»ãŒæ²æ» ããããšãã§ããã#ãã¯æŠ20419an
Â
Â
ãããããã§æ©ãã§ãŠã
é£äºãæãã®ã
Â
ã¹ãã¬ã¹ãæããŠã人ã«
å°ãã§ãå¿ã楜ã«ãªãã°å¹žãã§ãã
Â
Â
ãªããªãããããã®åå ã®1ã€ã«
ãã¹ãã¬ã¹ããããã®ã§ãã
Â
Â
ãªã®ã§ãæ¯éæåŸãŸã§èŠãŠé ããŠ
ãã®æ å ±ãèªåã®ãã®ã«ããŠäžãã
Â
Â
ããã§ã¯ã»ã»ã¬ãããŽãŒ( ïŸÐïŸ)ïŒïŒïŒ
Â
Â
Â
Â
Â
âãã€ã³ã
Â
âãã§ã³ã¬ãŒããªã©ã®å¶éã§ã
ããããæ¹åãããšããã³ã¹ã¯ãªã
Â
âãã§ã³ã¬ãŒãã®ã«ã«ãªã®æåã¯
ãããã®æªåå åã«ãªããªããš
Â
âè¡ç³å€ã®äžæã
ãããã®æªåã«åŒ·ãé¢äžãã
Â
Â
Â
é£äºã®ããããžã®åœ±é¿
Â
èªè ã®æ¹ã¯ããããæªåããã
é£ã¹ç©ãšããŠæãæµ®ãã¶ãã®ã¯
äœã§ããããïŒ
Â
âãã§ã³ã¬ãŒã
âçããã®
âãã«ã¯
âèã£ãããã®ãªã©
Â
Â
ãã£ããæãããšãããªæãããªïŒ
Â
ããããçµè«ããèšããš
ãããã®å¶éã«ãã
Â
ããããæ¹åããããšã瀺ã
ååãªãšããã³ã¹ã¯ãªãã§ã1ïŒã2ïŒ
Â
Â
ãªã®ã§å ·äœçãªãšããã³ã¹ã
瀺ããªãããããã«è¡ç³å€ãš
ããããšã®é¢ä¿ã«ã€ããŠãè¿°ã¹ãŠã¿ãã
Â
Â
âPoint
ãã§ã³ã¬ãŒããªã©ã®å¶éã§ãããããæ¹åãããšããã³ã¹ã¯ãªã
Â
Â
âè£è¶³
ãšããã³ã¹ïŒè±: evidenceïŒãšã¯ãã蚌æ ããè£ä»ãããç§åŠçæ ¹æ ããããã¯ã圢跡ããšãã£ãæå³ã§çšããããèª
Â
Â
Â
Â
Â
ãã§ã³ã¬ãŒããšç€ç¡
Â
ãã§ã³ã¬ãŒããšãããã®é¢ä¿ã«
ã€ããŠã¯1969å¹Žã«æ¢ã«å ±å3ïŒãããã
Â
Â
âå®é𿹿³
ééãã«ããªãŒãã»ãŒåãã«ãããã§ã³ã¬ãŒãã®æåãå«ããã§ã³ã¬ãŒãããŒãšå«ãŸãªããã©ã»ãããŒãç¡äœçºã«å²ãä»ããŠããããã4é±éé£ãã3é±éã®ç©ºçœæéã®åŸã«ä»æ¹ã®ããŒã4é±éé£ããã¯ãã¹ãªãŒããŒè©Šéšãè¡ãããŠããã
Â
Â
çç¶ã®æªåãäžå€ãæ¹åãªã©ã
調ã¹ãçµæã¯ãã§ã³ã¬ãŒããš
åœç©ã«å·®ããªã
Â
ãã§ã³ã¬ãŒãã®ã«ã«ãªã®æåã¯
æªåå åã«ãªããªããšçµè«ã¥ããŠããã
Â
Â
ããããã®äžæ¹ã§å°èŠæš¡ã§ã¯ããã
100ïŒ ã«ã«ãªããŠããŒãæåãã
Â
äºéç²æ€è©Šéšã§ç€ç¡ã
èªçºãããšããå ±åããã
ä»åŸãããªãæ€èšãåŸ ãããã
Â
Â
Â
âPoint
ãã§ã³ã¬ãŒãã®ã«ã«ãªã®æåã¯ãããã®æªåå åã«ãªããªã
Â
Â
Â
Â
Â
Glycemic loadãšããã
Â
åã®ãšããã§ããã§ã³ã¯ãããã
æªåãããªããšããŸããã
Â
ããã¯ã詳现ã«èŠãŠãããš
ããã§ã³ã¬ãŒãã®ã«ã«ãªæåãã¯
Â
ãããã®æªåãšé¢ä¿ãªããšãªã
å°ããããããè§£éãæ±ããããŸãã
Â
Â
ãçµå±ã©ã£ã¡ããããã¿ãããªïŒç¬ïŒ
Â
ããã§èŠãŠããããã®ã
ãè¡ç³å€ãã®ååšã§ãã
Â
Â
ããããæªåããã仮説ãšããŠ
é«ã€ã³ã¹ãªã³è¡çã
ãããã®çºçã«é¢äžãã
Â
Â
ãšããèããããã
è¡ç³å€ãæ¥æ¿ã«äžæãããªãé£äºã
ãããã«ã¯æãŸãããšãããŠããã
Â
Â
è¡ç³å€ã«é¢ããèšèã§
ã»ã«ã³ãããŒã«å¹æãšã
è¡ç³ã¹ãã€ã¯ã£ãŠãåç¥ã§ããããïŒ
Â
Â
éå»ã«ãã®èŸºã®å 容ã
èšäºã«ããŠãã®ã§ãã¹ã¹ã¡ããŠãŸãã
Â
Â
Â
ãããªãã§ãïŒåçªïŒ
Â
çŸåšã§ã¯ç³è³ªéã§ã¯ãªã
è¡ç³å€ãã©ã®çšåºŠæ¥æ¿ã«äžãããã
Â
å¥åº·ãç¶æããäžã§éèŠèŠãããŠ
ãã®éã«ç¥ã£ãŠæ¬²ããã®ã
Â
glycemic indexïŒGIïŒ
glycemic loadïŒGLïŒã§ããã
Â
Â
âGlycemic Index ïŒGIïŒãšã¯
ç³è³ªãå«ãé£åã®è¡ç³äžæäœçšãç€ºãææ°ã
Â
GIå€ãé«ãã»ã©
è¡ç³äžæäœçšã匷ããšãããŠããã
Â
Â
GIå€ã55ãŸã§ã¯äœGI
70以äžã¯é«GIãšããããŠããã
Â
Â
æ¬æ¥ã¯äœGIé£ã奚ããããšã§
ç³å°¿ç ã®ã³ã³ãããŒã«ã
æ¹åããç®çã§äœæãããã
Â
Â
ãã»ãªãããã®äœGIé£ã§ããããïŒ
ãã£ã±ãé£ã¹ãŠãè¡ç³å€äžãããããïŒã
Â
Â
ãããªæã«æŽ»çšã§ããã®ã
Glycemic Load ïŒGLïŒãšããæŠå¿µã§ãã
Â
Â
âGlycemic Load ïŒGLïŒãšã¯
GIãæåããç³è³ªéã§è£æ£ãããã®ã
Â
GLïŒGI à ç³è³ªé ÷ 100ãšãªã
Â
ã€ãŸãGIãäœããŠãå€éã«æåããã°
è¡ç³å€ã¯äžæãããšããããšã
Â
Â
ex)ã«ã¬ãŒã©ã€ã¹
Â
GIå€ïŒ67
1åã®æåéã150 g
ç³è³ªã®å«æéã¯61 g
Â
Â
ãªãã«ã¬ãŒã©ã€ã¹ã®GLå€ã¯41ãšãªãã
Â
Â
ex)ãªã³ãŽ
Â
GIå€38
æåéã¯120 g
ç³è³ªã®å«æé15 g
Â
Â
åãããã«ãªã³ãŽã®å Žåã¯
GLå€ã6ãšãªãã
Â
Â
Â
Â
Â
æ¥éãªè¡ç³å€ã®äžæã¯
é«ã€ã³ã¹ãªã³è¡çãããããã
Â
Â
ãã®é«ã€ã³ã¹ãªã³è¡çã
âã¢ã³ããã²ã³ã®ç£çã亢é²
Â
âèèã§ã®SHBG ã®ç£çãæå¶ããŠ
ã¢ã³ããã²ã³ã®æŽ»æ§ãäžãã
Â
Â
çµæãšããŠã
ç®èã®åæ³äº¢é²ã«äœçšã
ãããã®æªåã«ç¹ããã
Â
Â
ãŸãé«ã€ã³ã¹ãªã³è¡çã¯
IGF-1ãé«ã
IGFBP-3ãäœäžãããããšã§
Â
æ¯æŒæã®è§åç°åžžã亢é²ããŠ
ãããã®æªåã«äœçšããã
Â
Â
GLã«é æ ®ããé£äºãæå°ããããšã§
ããããæ¹åãããšããå ±åããã4ïŒ
Â
Â
ãã©ã³ã¹ã®è¯ãé£äºã®äœGL矀ã§
åªäœã«ç®ç¹ãæžå°ããŠããã
Â
Â
ãããïŒçŸæç¹ã§ã¯äžå®ã®èŠè§£ã«
éããŠãããä»åŸã®æ€èšãåŸ ãããã
Â
Â
ãããã§æ©ãæ£è ã®å€ãã¯
ææ¥æã®äžé«çã§ããããšãã
Â
æé·ã«å¿ èŠãªåãã®ãªãæ 逿åã«
ã€ããŠãé æ ®ãå¿ èŠã§ãããšæšæž¬ã§ããã
Â
Â
泚æããŠæ¬²ããã®ã¯äœGLé£ã¯
çæ°Žåç©ãã€ãšãããšã¯
ç°ãªããšããããšã§ãã
Â
Â
解説ããããã«
ç³è³ªã®ãéãã§ã¯ãªã
ç³è³ªã®ã質ãã«æ³šç®ããèããªã®ã§ã
Â
Â
ãªã®ã§ãããããæ¹åãããªã
ãã©ã³ã¹ã®è¯ãé£äºã
æãããšãåŒ·ãæšå¥šããããÂ
Â
Â
âPoint
è¡ç³å€ã®äžæããããã®æªåã«åŒ·ãé¢äžãã
Â
Â
âè£è¶³
SHBG ïŒsex hormone binding proteinïŒ
IGF ïŒinsulin-like growth factorïŒ -1
IGFBP ïŒinsulin like growth factor binding proteinïŒ -3
Â
Â
Â
Â
Â
ãŸãšã
Â
âãã§ã³ã¬ãŒããªã©ã®å¶éã§ã
ããããæ¹åãããšããã³ã¹ã¯ãªã
Â
âãã§ã³ã¬ãŒãã®ã«ã«ãªã®æåã¯
ãããã®æªåå åã«ãªããªããš
Â
âè¡ç³å€ã®äžæã
ãããã®æªåã«åŒ·ãé¢äžãã
Â
Â
ããããèãããã®ã¯
åã«ãçãç©ãã§ãããã
Â
æªåãããšããèãã¯
é©åã§ã¯ãªãããç¥ããªãã
Â
Â
é£äºã«æããªã
è¡ç³å€ãäžããªãçºã®å·¥å€«ã ãš
è«æãèŠãŠãŠåãã£ãã
Â
è¡ç³å€ãäžããªã工倫ã«
é¢ããŠãèšäºã«ããŠãã®ã§
èŠããŠèŠãŠãè¯ããšæãã
Â
Â
ã§ãã(*'âœ')
Â
Â
æåŸãŸã§èŠãŠé ã
ããããšãããããŸãã
Â
Â
ãããããããã°ã
ãã®å 容ãè¯ãã£ããš
æãããã
Â
å€ãã®äººã«ç¥ã£ãŠ
é ãããå 容ãªã®ã§
Â
SNSçã§æ¡æ£ããŠ
é ãããšå¬ããã§ãã
Â
Â
Â
次å以éãå¥åº·ã«
Â
é¢ããæ å ±ã
Â
çºä¿¡ããŠãããŸãã®ã§ã
Â
ãããããé¡ãããŸãã
Â
Â
Â
æ°ã«ãªãããšãããã°
Â
ã©ãã©ãã³ã¡ã³ãããŠããŒ( ^Ï^ )
Â
Â
ããã§ã¯ãã°ãã°ãŒã(@^^)/~~~
Â
Â
Â
Â
â©YouTubeã¯ãã¡ãâ©
Â
Â
Â
Â
Â
â©Twitterâ©
ãããããã¹ã«ã¯
— æ±ããðŠè¬å€åž«saitorioïŒ å¥åº·ãªãã©ã·ãŒÃããã°ÃYouTube (@saitorio3) 2020幎4æ18æ¥
ãèµ·ãããµã€ã³ãããã
ðãã€ã³ãªããã®æ³å
äœãïŒã€å€§ããªäºæ ãèµ·ãã£ãã
ãã®é°ã«ã¯åãåå ã«ããå°ããªäºæ ã29ãããããã«ãããã®é°ã«ã¯ãäºæ ã«ãªããªãã£ããŸã§ããã²ããããšããããšãïŒïŒïŒãã£ãã¯ãã ãïŒãïŒïŒ29ïŒïŒïŒïŒã#ãã¹ #倱æ #ãã€ã³ãªããã®æ³å
Â
Â
Â
â©noteâ©
Â
Â
Â
åèæç®
1ïŒ Cao, H., Yang, G., Wang, Y., et al.: Complementary therapies for acne vulgaris, Cochrane Database Syst. Rev., 2015 Jan 19;1:CD009436. doi: 10.1002/14651858.CD009436.pub2.
Â
2ïŒ é«å±±æç±çŸïŒæã䌞åïŒç掻æå°ã®ã³ãããããæ£è ã® é£äºæå°ïŒDermatology, 170: 119â124, 2010.
Â
3ïŒFulton J. E. Jr., Plewig G., Kligman A. M.: Effect of chocolate on acne vulgaris. JAMA, 210: 2071â74, 1969.
Â
4ïŒKwon, H. H., Yoon, J. Y., Hong, J. S., Jung, J. Y., Park, M. S., Suh, D. H.: Clinical and histological effect of a low glycaemic load diet in treatment of acne vulgaris in Korean patients: A randomized, controlled trial. Acta Derm. Venereol., 92: 241â 246, 2012
Â
Â
æ¥æ¬éŠç²§ååŠäŒèªãVol. 40, No. 1, pp. 12â19 ïŒ2016ïŒ